Risk stratification and calculators

Slides:



Advertisements
Similar presentations
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Advertisements

CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
PEBB Disease Burden Report PEBB Board of Directors August 21, 2007 Bdattach.10.
Prediction Models in Medicine Clinical Decision Support The Road Ahead Chapter 10.
Vanderbilt Sports Medicine Chapter 4: Prognosis Presented by: Laurie Huston and Kurt Spindler Evidence-Based Medicine How to Practice and Teach EBM.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
The Diabetic Retinopathy Clinical Research Network Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for.
4/19/2017 Managing Patients With Ocular Hypertension Results From The Ocular Hypertension Treatment Study (OHTS) The American Glaucoma Society Michael.
November 2006 Prediction Model Template from OHTS-EGPS Pooled Analyses Today’s version is November 14.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Retinal Nerve Fiber Layer Loss and Quality of Life in Glaucoma Gracitelli CPB,
Association between Systolic Blood Pressure and Congestive Heart Failure in Hypertensive Patients Mrs. Sutheera Intajarurnsan Doctor of Public Health Student.
Will my Glaucoma patient lose vision ?
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Division of Population Health Sciences Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Diagnostic accuracy of the STRATIFY clinical.
RANDOMIZED CLINICAL TRIALS IN GLAUCOMA- WHAT DO THEY TELL US? Dr Jyoti Shetty B.W.Lions superspeciality eye hospital.
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
QUANTITATING THE IMPACT OF CLINICAL AND BASIC SCIENCE RESEARCH POSTER #2469 M. O. GORDON, C. SARLI, E. K. DUBINSKY, E. LONG, C. LA RUE, M. A. KASS, AND.
Al wakeel J, Bayoumi M, Al Ghonaim M, Al Harbi A, Al Swaida A, Mashraqy A.
Does Greater Long-Term IOP Variability Increase Probability of Primary Open Angle Glaucoma in the Ocular Hypertension Treatment Study (OHTS)? M.O. Gordon,
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.
Supporting Vascular Risk Assessment: QDScore Julia Hippisley-Cox 15 th April 2010.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
The latest from the Australian Study of Keratoconus Dr Srujana Sahebjada Postdoctoral Research Fellow/Optometrist Ocular Genetics Unit.
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
The Ocular Hypertension Treatment Study Group (OHTS)
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2013.
Genetic Susceptibility Variations and Visual Field Progression in Singaporean Chinese Patients with Primary Angle Closure Glaucoma 1 Duke-National University.
Management of Hypertension according to JNC 7
for Overall Prognosis Workshop Cochrane Colloquium, Seoul
PROTECTING CELLS IN THE EYE AT RISK OF DAMGE FROM GLAUCOMA
C Wilson, KM Rhodes, RA Payne
cross- sectional analyses of HEIJO-KYO Cohort
Ophthalmology – Raised IOP Referrals (Adults only)
Target IOP Update Mohamed Yasser Sayed Saif Beni Suef University
John Weeks1, MD Candidate 2017, Justin Hickman1, MD Candidate 2017
Patient Registries and Health Outcomes in Diabetes: A Retrospective Study Nipa Shah, MD1; Fern Webb, PhD1; Liane Hannah, BSH1; Carmen Smotherman, MS2;
Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Year 1 Results Lisa A. Hark, PhD, RD; Michael Waisbourd, MD; Kamran Rahmatnejad, MD;
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
VUmc Basispresentatie
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the Irish Longitudinal Study on Ageing.
Lasers in Glaucoma: Meta analysis
Effect of Selective Laser Trabeculoplasty on
Evaluating Policies in Cardiovascular Medicine
Κολπικη μαρμαρυγη σε ασθενεις με αποφρακτικη υπνικη απνοια
Global prevalence of POAG
Glaucoma.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
JAMA Ophthalmology Journal Club Slides: Validity of the Age-Related Eye Disease Study Grading Scale Vitale S, Clemons TE, Agrón E, et al; Age-Related Eye.
Neil J. Stone et al. JACC 2014;63:
Implications for Nursing Practice Design and Methodology
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Associate Professor of Ophthalmology
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study by James P Sheppard, Kate Fletcher, Richard J McManus,
JAMA Pediatrics Journal Club Slides: Association of Salivary MicroRNA Changes With Prolonged Concussion Symptoms Johnson JJ, Loeffert AC, Stokes J, et.
Table of Contents Why Do We Treat Hypertension? Recommendation 5
MEDICAL ELIGIBILITY CRITERIA
Contemporary Evidence-Based Guidelines
JAMA Ophthalmology Journal Club Slides: Generational Differences in the 5-Year Incidence of Age-Related Macular Degeneration Cruickshanks KJ, Nondahl DM,
ASCORE : An up-to-date cardiovascular risk score for hypertensive patients reflecting. contemporary clinical practices developed. using the ASCOT trial.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Improving Overlap Farrokh Alemi, Ph.D.
Risk Factor Analysis (II)
Winthrop University Hospital
The Effect of Corneal Thickness on Ocular Drug Penetration
Presentation transcript:

Risk stratification and calculators Dr Parul Ichhpujani MS, MBA(HA) Associate Professor Glaucoma and Neuroophthalmology Service Government Medical College and Hospital Chandigarh, India Predicting the development of glaucoma from ocular hypertension is a cornerstone to deciding on whether or not to treat. Risk calculators may be an innovative approach to simplify the management of ocular hypertension and glaucoma patients and provide evidence-based treatment. No Financial Disclosures

Glaucoma Continuum

Risk factors: Strength of evidence Risk stratification: Roots in Cardiovascular medicine; Framingham Study Similarities between CHD and Glaucoma: Chronic disease; modifiable risk factors Globally, the prevalence is thought to be higher in African and Japanese populations (Kyari et al ., 2013), in males and in those living in urban areas. Worley A. Australian Journal of Primary Health, 2011; 17: 233–9

Risk Factors: Major RCTs

Ocular risk factors: Consensus Guidelines Parameter Independent Predictive factor Independent Risk Factor IOP + CCT Insufficient evidence IOP Fluctuation + Provocative tests Low OPP Low CH Myopia Disc hemorrhage

To treat or not to treat? Ocular hypertension and Suspects What to do with these patients? How often should they be examined? Is preventative treatment effective? Who should be treated? Large range of predictions, sometimes differing from the actual risk by 40% Ophthalmologists’ estimate of risk (%) and whether or not they would treat. Dashed represents the risk calculator estimate. Mansberger SL.J Glaucoma 15:426--31, 2006

Risk of Progression Unilateral vision loss: Relevant conservative end point. Risk of Progression to functional impairment is linear. 15 yr period is relevant for the disease Olmsted Co. results (treated patients) can conservatively be used to estimate progression in untreated patients. Treatment may reduce the risk of progressing from untreated OHTN to blindness between 1.2% and 8.1% over 15 years.

Basis of Risk calculators: Cut down the math OHTN to POAG in 5years OHTS and EGPS Multivariate Regression Analysis: Increasing age, thin CCT, increase C:D ratio, and higher PSD index in VF. Even if one simplifies the continuous variables of age, CCT, IOP, and PSD into thirds and uses 9 different combinations for C/D (0.0--0.8), 729(3X 3x 3X 3 X9)different results exist for OHTN patients; creating large number of different combinations. Provided the basis for the development and validation of the prediction models available today. Arch Ophthalmol. 2004;122:813–820 Ophthalmology. 2007;114(1):3–9

Educated Guesswork to Risk calculators Variables Risk Score STAR (2002) Age, IOP, CCT, VCDR, VF PSD, DM 5yr risk of glaucoma, if left treated STAR II (2005) Age, IOP, CCT, VCDR, VF PSD Dever’s (2002) 5yr risk of glaucoma; with Rx Vs. No Rx Glaucoma 5 year (2006) Age, Mean IOP, CCT, VCDR, VF PSD Estimated 5yr risk of developing POAG Medisoft IOP, HRT, VF PSD Factors Overlooked: Family history, race, myopia, PEX, pigment dispersion, DM and cardiovascular disease.

STAR: Scoring Tool for Assessing Risk STAR II Based on OHTS 6 variables Kass, 2002 126 patients with OHT were followed as part of DIGS; to calculate the c-index. c-index: 0.7 5 variables: DM excluded Mederios, 2005 Risk stratification: Low: <5% Moderate: 5-15% High: > 15% Arch Ophthalmol. 2005;123:1351–60.

Devers Eye Institute Risk calculator Data only from OHTS https://www.deverseye.org/grc/index.cfm

Glaucoma 5 yr risk estimator http://ohts.wustl.edu/risk/formula.html. Calculator truncates predictor values at the bounds of the values recorded for each predictor in the OHTS-EGPS cohort Medisoft Pointwise linear regression available in the Progressor (Medisoft Ltd, Leeds, UK) Arch Opthalmol. 2002;12(6):701–830.

Two Methods for Glaucoma 5 yr risk estimator Continuous method: Actual Values Point method: Range of age and average value of measurements

Calculators on Smartphones/Tablets Glaucoma Calc S.T.A.R II

Impact of Risk Calculation Using simulated case scenarios consistent with the population of the OHTS, average treatment threshold for 56 glaucoma specialists was seen: 23% chance of developing glaucoma over a 5-year period when they did not have the results of a risk calculator 17% when they were provided with the risk calculator J Glaucoma. 2008;17:631-8.

Threshold to treat Calculator http://oil.wilmer.jhu.edu/threshold At what IOP should the Rx be started? Caveat: Static measurements of IOP, even if repeated, do not capture short- term fluctuation or peak IOP J Glaucoma. 2014;23(8):485-6.

Which Calculator is better? C-index: Measure of the discriminating ability of a model. Closer the c-index gets to 1, better the discriminating ability of model. STAR II: 0.7 Glaucoma 5 year Risk Estimator: 0.74 No head to head study to compare the different risk calculators available. STAR II : Most widely used, available on smart phone

Caveats in OHTS based calculators Can only be used for patients with similar demographics to the participants of OHTS and EGPS Cannot predict rate of progression of glaucoma. Not useful for patients with established disease.

Risk calculator for patients with treated glaucoma?? Prediction model Moderate accuracy in estimating future VF outcomes in an independent glaucoma population Generated Two equations : Provides the risk of glaucoma progression (%) based on pre-defined PLR criteria in a given number of years, Estimates future rates of VF change based on clinical characteristics. C-Index: 0.78 Good agreement; Invest Ophthalmol Vis Sci. 2012 ; 53(6): 2702-7.

So, All We Need Is a Good Risk Calculator, Right? Wrong!

Benefit to patients Treatment patient-centered rather than population- based. Patients are more likely to adhere to therapy if they have a more definitive expectation of risk

Future… Intelligent programming; Cloud based EMR An EMR system programmed to consider all of the factors that are known to be associated with a higher risk of glaucoma? What if your EMR system had instant access to all of the data from millions of patient encounters over many years? “Our imagination is the only limit to what we can hope to have in the future.” ….Charles Kettering

Take Home Message Just as cholesterol levels are changing in regards to the CHD risk model, so is IOP and other factors in regard to the OHTN risk calculator. One size doesn’t fit all Don’t use as a cookbook but as adjunct information.

Thank You!! itsdrparul@gmail.com